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Abstract
The potential role of Sirt1 and Sirt2 subtypes of Sirtuins (class III  NAD+-dependent deacetylases) in the pathogenesis of 
Huntington’s disease (HD) has been extensively studied yielding some controversial results. However, data regarding the 
involvement of Sirt3 and their variants in HD are considerably limited. The aim of this study was to assess the expression 
pattern of Sirt1 and three Sirt3 mRNA isoforms (Sirt3-M1/2/3) in the striatum, cortex and cerebellum in respect of the effect 
of gender, age and the presence of the transgene using the N171-82Q transgenic mouse model of HD. Striatal, cortical and 
cerebellar Sirt1-Fl and Sirt3-M1/2/3 mRNA levels were measured in 8, 12 and 16 weeks old N171-82Q transgenic mice and in 
their wild-type littermates. Regarding the striatum and cortex, the presence of the transgene resulted in a significant increase 
in Sirt3-M3 and Sirt1 mRNA levels, respectively, whereas in case of the cerebellum the transgene resulted in increased 
expression of all the assessed subtypes and isoforms. Aging exerted minor influence on Sirt mRNA expression levels, both in 
transgene carriers and in their wild-type littermates, and there was no interaction between the presence of the transgene and 
aging. Furthermore, there was no difference between genders. The unequivocal cerebellar Sirtuin activation with presumed 
compensatory role suggests that the cerebellum might be another key player in HD in addition to the most severely affected 
striatum. The mitochondrially acting Sirt3 may serve as an interesting novel therapeutic target in this deleterious condition.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neu-
rodegenerative disease [66]. HD is caused by expansion of 
CAG repeats in the IT15 gene encoding Huntington pro-
tein (Htt) which has an important role in the maintenance 
of cellular energy metabolism and mitochondrial function 
[50]. Previous works demonstrated that mutant Hunting-
ton protein (mHtt) inhibits the function of a key metabolic 
master regulator, namely peroxisome proliferator-activated 
receptor-gamma coactivator 1α (PGC-1α), which, amongst 
others, has an essential role in mitochondrial biogenesis [8, 
25].
Sirtuins are class III  NAD+-dependent deacetylases [38]. 
Currently there are seven identified mammalian Sirtuin sub-
types (SIRT1-7), which are localized in different cellular 
compartments (nuclear: SIRT1 (the mammalian orthologue 
of the yeast Silent information regulator 2 protein (Sir2)), 
-6, -7; mitochondrial: SIRT3, -4, -5; cytoplasmatic: SIRT2) 
[36]. In addition to the above-detailed subtypes, alterna-
tive splicing results in further isoforms of Sirtuins [31, 67]. 
Several molecular targets of Sirtuins, including the above-
mentioned PGC-1α, were identified as participants of the 
regulation of energy metabolism, circadian rhythm, stress 
response, apoptosis and aging [38]. The association between 
SIRTs and neurodegenerative disorders, including HD, has 
been widely studied using these models [2, 22, 24, 27, 36, 
56]. Calorie restriction is capable of increasing SIRT1 pro-
tein level in the brain, liver, hearth and white adipose tissue 
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of mice [39], and also increases the lifespan in the N171-
82Q transgenic (tg) mouse model of HD [11]. In contrast 
to these findings, exercise, which induces the expression 
of Sirt3-M1 and -M2 isoforms [47], did not elongate the 
lifespan in the same mouse model of HD [43]. Regarding 
Sirt1 mRNA and SIRT1 protein expression changes in HD 
the results are somewhat inconsistent: SIRT1 protein lev-
els were found to be reduced in human brain tissue and in 
the R6/1 transgenic mouse model of HD as well [18, 41]. 
Tulino et al. found that SIRT1 activity becomes reduced in 
R6/2 (with a mean CAG repeat number (MRN) of 204) and 
HdhQ150 (MRN: 165) mice, in the background of which 
they hypothesized altered phosphorylation status of SIRT1 
via an 5′ AMP-activated protein kinase α1-related mech-
anism in the striatum and cerebellum [61]. Although the 
presence of the transgene did not affect either Sirt1 mRNA, 
or SIRT1 protein expression in the striatum of R6/2 mice, 
there was a significant decrease in mRNA expression from 
4 to 9 weeks in wild-type (wt) animals [61]. In contrast to 
these findings, cerebellar Sirt1 mRNA expression increased 
significantly by 9 and 14 weeks of age in R6/2 mice, whereas 
SIRT1 protein levels significantly decreased predominantly 
in wt mice by 14 weeks of age. In HdhQ150 and wt mice 
the SIRT1 protein level did not show any alteration either in 
the 2 or in the 22 months old animals [61]. A later whole-
brain study reported the elevation of Sirt1 mRNA level in 
5, 8 and 11 weeks old R6/2 mice (MRN: 144). However, 
up-regulation of Sirt1 was only observed in their 8, but 
not in 12 weeks old counterparts possessing a mean CAG 
repeat size of 182 [45]. Regarding SIRT1 protein expres-
sion, there was a consistent elevation in tg mice with 182 
mean CAG repeats in both ages, and when examined at 12 
weeks of age, without gender differences [45]. Besides the 
somewhat inconsistent findings obtained from the above-
mentioned studies, the experiments influencing the expres-
sion of SIRT1 or of its orthologues from a therapeutic point 
of view yielded more controversial results. Parker et al. 
were the first who demonstrated that Sir2 overexpression 
and resveratrol (RESV) treatment (one of the most important 
non-selective Sirtuin inducer) could delay the development 
of neuronal dysfunction in a Caenorhabditis elegans model 
of HD (Htt N-terminal fragment, 128Q) in vivo [42]. They 
also reported that RESV prevented the striatal neuronal cell 
death in HdhQ111 knock-in mice [42]. To test the potential 
neuroprotective effect of SIRT1, Jeong et al. crossed a brain-
specific Sirt1 knockout mice (BSKO; genotype: Sirt1flox/flox) 
with the R6/2 HD model mice [22]. They detected the exac-
erbation of the neuropathological aspects of HD indicated 
by lower striatal (neuronal) volume [22], whereas they found 
the opposite in SIRT1 overexpressing knock-in mice (Sirt1-
KI-R6/2). These animals showed longer survival time (30% 
extension) and less prominent neuropathological alterations 
[22]. They proposed that the neuroprotective effect of SIRT1 
is exerted through the activation of the cyclic AMP response 
element binding transcription factor-regulated transcription 
coactivator 1 factor, which leads to the enhancement of the 
brain-derived neurotropic factor-mediated neuroprotection 
[22]. Jiang et al. crossed Sirt1 and N171-82Q or BAC HD 
transgenic mice which resulted in offsprings with decel-
erated disease progression and reduction of brain atrophy 
probably via the overexpression of Sirt1 [24]. In contrast to 
these findings, the pharmacological inhibition of SIRT1 by 
selisistat exerted beneficial effects in both Drosophila and 
mouse models of HD and was found to be safe in human 
studies as well [52, 54].
SIRT2, another member of the Sirtuin family, is sus-
pected to enhance the disease process in HD. Chopra et al. 
reported a beneficial effect of SIRT2 inhibition in R6/2 HD 
mice [7]. Previously published articles demonstrated that 
there is an age-dependent SIRT2 accumulation which results 
in microtubule deacetylation in mouse brain and spinal cord 
[33]. These alterations lead to the disruption of microtubule-
associated cellular transport which is an important compo-
nent of the pathogenesis of HD [10, 16]. However, it seems 
that the ablation of SIRT2 did not prevent the development 
of HD-related pathological mechanisms in R6/2 mice [5].
Similar to SIRT1, for which most of the results support 
a protective role in HD, SIRT3 is also proposed to have a 
beneficial effect regarding the pathogenesis of the disease 
[38], though the available data are limited. SIRT3 is involved 
in the regulation of fatty acid oxidation, urea- and amino 
acid pathways [2]. Striatal administration of a RESV dimer 
(ε-viniferin treatment) reduced ROS level through SIRT3-
mediated superoxide dismutase 2 (SOD2) induction in 
striatal progenitor cells (Hdh(Q111)) [14]. Some authors 
suggested that SIRT3 could alleviate the pathological pro-
cess in HD through the deacetylation of the mitochondrial 
complexes (I, II, V) as well [1, 2]. Furthermore, SIRT3 is 
implicated in autophagy regulation via its effect on chaper-
ones [28].
Regarding the role of another Sirtuin isoforms (SIRT4-7) 
in the pathogenesis of HD, experimental data are lacking.
The aim of the current study was to further elucidate 
the role Sirt1 and Sirt3 isoforms with presumed beneficial 
effects in HD, because the available data are somewhat con-
troversial regarding Sirt1, and no deep assessment was done 
regarding the M1, M2 and M3 isoforms of Sirt3. For that 
purpose the authors applied a multi-dimensional approach 
to simultaneously assess the effect of the transgene, the time 
course of the disease and their interaction as well in addition 
to the screening of regional and possible gender-related dif-
ferences in the N171-82Q tg mouse model of HD.
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Materials and Methods
Animals
8, 12 and 16 weeks old N171-82Q and as their control, 
B6C3 wt mice with identical genetic background (female 
and male animals distributed equally) were involved in this 
study (n = 6–7 in each group). The HD model mice origi-
nally came from Jackson Laboratories (USA). They were 
housed in cages under standard conditions with 12–12 h 
light-dark cycle. The food and water were freely available. 
The experiments were carried out in accordance with Euro-
pean Communities Council Directive (86/609/EEC) and 
were approved by the local animal care committee. All ani-
mals were euthanized via isoflurane overdose (Forane; Abott 
Laboratories Hungary Ltd., Budapest, Hungary).
Sample Handling
The brains were rapidly removed from the skull and both 
hemispheres were dissected into the following brain areas: 
striatum, cortex and cerebellum. The tissue samples were 
stored at − 80 °C until the RT-PCR analysis.
RT‑PCR Analysis
To perform the RT-PCR analysis, total RNA was isolated 
from the striatal, cortical and cerebellar samples with Tri-
zol reagent according to manufacturer’s protocol (Molecu-
lar Research Center, USA). The RNA concentration was 
determined with MaestroNano spectrophotometer. The 
RNA integrity was certified by 1% gel electrophoresis. For 
cDNA synthesis 1 µg of total RNA, random hexamer prim-
ers and reverse transcriptase were used (Revert Aid First 
Strand cDNA Synthesis Kit; Thermo Scientific, USA). The 
synthesized cDNA was stored at − 20 °C. Real-time PCR 
analysis (CFX 96 Real Time System; Bio-Rad, USA) with 
various Sirtuin primers was performed in 20 µl final vol-
ume using syber green label (PCR Biosystems, USA) [47]. 
Primer sequences and the exact thermal cycling conditions 
are described in our previous work [47]. We used the 18S 
rRNA as endogenous control (Applied Biosystems, USA). 
To calculate the relative mRNA expression levels, we used 
the  2−∆∆Ct method [30].
Statistics
All statistical calculations were performed with the use of 
the freely available R software (R Development Core Team). 
First, the relative mRNA expression levels were calculated 
separately regarding each gene (i.e., Sirt1 or Sirt3), but they 
were normalized to the striatal level of the main subtype 
or isoform (i.e., Sirt1-Fl and Sirt3-M1) of 8 weeks old wt 
mice in each case to allow a time course analysis of the 
changes of expression patterns. Then we checked the dis-
tribution of data populations with the Shapiro–Wilk test 
and the homogeneity of variances with the Levene’s test. 
In several cases the data diverged from Gaussian distribu-
tion and the variances were not equal. For that reason, we 
applied the Sheirer-Ray-Hare test to determine the differ-
ences between the investigated factors and their interaction 
as well. Afterwards, we carried out permutation t-tests as 
post hoc analysis for pairwise comparison and Type I errors 
from multiple comparisons were controlled with false dis-
covery rate. As some of the possible comparisons would not 
have yielded meaningful information regarding the a priori 
decided presumptions, a maximum of 9 pairwise compari-
sons were implemented in case of each subtype or isoform 
analyzed by each brain region. The results were considered 
significant when the corrected p values were greater than 
0.05. The data were presented as median and 1st and 3rd 
quartiles (Figs. 1, 2, 3, 4, 5).
Results
We could not detect any significant difference between 
male and female mice regarding the expression of any 
of the assessed Sirtuin isoforms either in the wt or in the 
tg groups, so they were pooled for further analyses. Fur-
thermore, in respect of Sirt1 and Sirt3 expression, no inter-
action was found between the presence of the transgene 
and aging. Focusing on their separate effects, there was 
a significant elevation of Sirt1-Fl (full length) expres-
sion in all the cortical and cerebellar samples of 8, 12 
and 16 weeks old tg animals compared to wt mice (cortex 
(8 weeks: p = 0.0029; 12 weeks: p = 0.0018; 16 weeks: 
p = 0.0029); cerebellum (8 weeks: p = 0.0052; 12 weeks: 
p = 0.0054; 16 weeks: p = 0.0065), but not in the striatum 
(Figs. 1 and 5). Regarding the effect of aging on Sirt1-Fl 
expression levels, we detected significant increase only in 
the cerebellum of tg group at 16 weeks of age (8 vs. 16 
weeks: p = 0.0245; 12 vs. 16 weeks: p = 0.0316). There 
was no detectable change in Sirt3-M1 expression in the 
striatum and cortex of any age groups (8, 12, 16 weeks). 
In contrast, there was a clear elevation of Sirt3-M1 mRNA 
expression in cerebellar samples of all age groups of tg 
animals compared to wt mice (8 weeks: p = 0.0024; 12 
weeks: = 0.0024; 16 weeks: p = 0.0024; Figs. 2 and 5). We 
could not observe any age-related effect in the Sirt3-M1 
isoform in either group. Regarding Sirt3-M2 we could not 
detect any difference between wt and tg groups in the stri-
atal and cortical samples, but we could identify a signifi-
cant elevation in the cerebellum of tg animals in each age 
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group compared to wt controls (8 weeks: p = 0.0021; 12 
weeks: p = 0.0012; 16 weeks: p = 0.0021; Figs. 3 and 5). 
When assessing the effect of aging on Sirt3-M2 expression 
levels, we detected significant decrease only in the cortex 
of wt group at 16 weeks of age (8 vs. 16 weeks: p = 0.038; 
12 vs. 16 weeks: p = 0.038). The expression of Sirt3-M3 
elevated in each striatal and cerebellar tg groups, but only 
in the 16 weeks old group in the tg cortex compared to wt 
mice (striatum (8 weeks: p = 0.0097; 12 weeks: p = 0.0054; 
16 weeks: p = 0.0097); cortex (16 weeks: p = 0.0032); 
cerebellum (8 weeks: p = 0.002; 12 weeks: p = 0.0006; 16 
weeks: p = 0.0016) (Figs. 4 and 5). In the striatal Sirt3-M3 
samples there was detectable decrease of expression by 12 
weeks of age in both wt and tg animals (8 vs. 12 weeks 
(wt-wt): p = 0.0243; 8 vs. 12 weeks (tg–tg): p = 0.036).
Discussion
HD is a neurodegenerative disorder, which has currently no 
curative treatment, but encouraging clinical trials are ongo-
ing (e.g. antisense oligonucleotide treatment) [13, 56]. These 
therapeutic approaches target the pathological trinucleotide 
repeat expansion in the mutant hunting in mRNA, the extent 
of which has been demonstrated to have the strongest asso-
ciation with the age of disease onset and severity [12, 26, 
37]. However, other important influencing factors of the dis-
ease have already been identified as well, which may serve 
as good candidates for the augmentation of beneficial effects 
obtained by the currently available therapies [32, 64].
Sirtuins are surely involved in the neurodegenerative pro-
cess in HD, however, there are controversial results regard-
ing their role [36, 38, 45, 61]. Further studies are needed to 
clarify these controversies and to better explore the role of 
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Fig. 1  Relative mRNA expression level of Sirt1-Fl in the striatum 
(a), cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 
wild-type mice of three age groups. The Sirt1-Fl level significantly 
elevated in all cortical and cerebellar samples in each age group of 
tg animals compared to wt mice. Aging caused a significant increase 
only in the cerebellum of tg group by 16 weeks of age. For clarity, the 
levels of significance were indicated separately in Fig. 5 in a special 
table format. Values are plotted as medians and interquartile ranges; 
tg = transgenic, wt = wild-type, w = weeks
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Fig. 2  Relative mRNA expression level of Sirt3-M1 in the striatum 
(a), cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 
wild-type mice of three age groups. The Sirt3-M1 level was signifi-
cantly elevated in all cerebellar samples in each age group of tg ani-
mals compared to wt mice. For clarity, the levels of significance were 
indicated separately in Fig.  5 in a special table format. Values are 
plotted as medians and interquartile ranges; tg = transgenic, wt = wild-
type, w = weeks
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different Sirtuin subtypes and isoforms obtained by alterna-
tive splicing [2, 22, 24, 27, 36, 56]. Accordingly, we aimed 
at contributing to the clarification of the controversies 
regarding Sirt1 and Sirt3 mRNA expression patterns by a 
better characterization of region- and aging-specific changes 
in the mRNA expression levels of Sirt1 and three Sirt3 iso-
forms using the N171-82Q tg mouse model of HD.
Tulino et al. found a significant decrease in striatal Sirt1 
mRNA expression from 4 to 9 weeks in the wt group, 
whereas cerebellar Sirt1 mRNA expression increased 
significantly by 9 and 14 weeks of age in the same con-
trol group in experiments with R6/2 mouse model of HD 
(MRN: 204) [61]. The presence of the transgene seemingly 
did not affect Sirt1 mRNA expression. Another research 
group (Reynolds et al.) measured Sirt1 mRNA levels in 
the whole-brain samples of 5, 8, 11- (MRN: 144) and 8, 12 
weeks old (MRN: 182) R6/2 mice [45]. In the 5, 8 and 11 
weeks old mice (MRN: 144) there was a significant increase 
in mRNA levels of all tg groups. Aging did not affect the 
values and accordingly there was no significant interaction 
between age and the presence of the transgene. Regarding 
the only female cohort with 182 mean CAG repeat size, the 
significant increase could be observed only in the 8 weeks 
old group [45]. Due to the different CAG repeats, ages, 
brain regions and gender composition the comparability of 
these results is limited. Therefore, we find it important to 
get closer to the unbiased preclinical modelling of changes 
in Sirt1 mRNA expression in HD. Thus, we paid a special 
attention to study design regarding the following points: we 
used the N171-82Q tg model of HD, because the phenotype 
of these mice mimics better the majority of human cases 
with considerable similarities in pathological alterations as 
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Fig. 3  Relative mRNA expression level of Sirt3-M2 in the stria-
tum (a), cortex (b) and cerebellum (c) of N171-82Q transgenic and 
B6C3 wild-type mice of three age groups. The Sirt3-M2 level was 
significantly elevated in all cerebellar samples in each age group of 
tg animals compared to wt mice. Aging caused a significant decrease 
only in the cortex of wt group by 16 weeks of age. For clarity, the 
levels of significance were indicated separately in Fig. 5 in a special 
table format. Values are plotted as medians and interquartile ranges; 
tg = transgenic, wt = wild-type, w = weeks
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Fig. 4  Relative mRNA expression level of Sirt3-M3 in the striatum 
(a), cortex (b) and cerebellum (c) of N171-82Q transgenic and B6C3 
wild-type mice of three age groups. The Sirt3-M3 level was signifi-
cantly elevated in all striatal and cerebellar samples in each age group 
of tg animals compared to wt mice. The striatal expression decreased 
significantly by 12 weeks of age in both wt and tg animals. For clar-
ity, the levels of significance were indicated separately in Fig. 5 in a 
special table format. Values are plotted as medians and interquartile 
ranges; tg = transgenic, wt = wild-type, w = weeks
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well than the R6/2 tg mice, the symptoms of which mainly 
resemble that of juvenile HD cases. Furthermore, the authors 
have extensive previous experiences with this model [15, 35, 
40, 59, 62, 63, 68, 69], which enables the drawing of indirect 
correlations between the characteristic features of disease 
progression with the time course of the changes in mRNA 
expression patterns. Characteristically, in N171-82Q mice 
the symptoms begin to develop at approximately 2 months 
of age and disease progression results in a mean survival 
time of 110–130 days [68, 69]. Accordingly, the study of 
mice at the age of 8, 12 and 16 weeks may represent early, 
moderate and advanced stages of the modelled disease. In 
addition to the assessment of the presence of transgene on 
Sirt mRNA expression changes in key structures (striatum, 
overlying cortex, cerebellum) of the regulation of motor 
functions, our study design involved the determination of 
the effect of aging and its interaction with the presence of the 
transgene with a view on gender-related effects as well. First 
of all, we found no significant differences between genders 
regarding either of the above-mentioned aspects, and there-
fore gender issues seemingly did not introduce bias into the 
studies of Tulino et al. and Reynolds et al. [45, 61]. Similarly 
to the study of Tulino et al. [61], we found no effect of the 
transgene in the striatum regarding either age groups, but 
a marked increase in Sirt1 expression was demonstrated in 
cortical and cerebellar samples of tg animals compared to 
wt controls in all age groups similar to that found by Reyn-
olds et al. [45] applying whole brain samples. The magni-
tude of difference increased only by 16 weeks of age, and 
again, similarly to the latter study, no significant interaction 
was found between aging and the presence of the transgene. 
Aging-related increase in Sirt1 mRNA expression either in 
the striatal or cerebellar samples of wt mice, found by Tulino 
et al. [61], could not be confirmed by the current study.
Although data suggest that the induction of mitochon-
drially acting SIRT3 may be capable of exerting benefi-
cial effects in a HD model [14], the expression pattern of 
Sirt3 mRNA isoforms has never been studied in any HD 
model. Similar to that found in case of Sirt1-Fl, a remark-
able increase of cerebellar expression of all Sirt3 isoforms 
could be observed in tg animals compared to wt controls in 
the current study. The striatal expression of Sirt-M3 in all 
age groups and the cortical expression of Sirt3-M3 by 16 
weeks of age were found to be increased. However, we have 
to note here that the relative expression level of Sirt3-M3 
mRNA is considerably lower compared to that of the other 
Fig. 5  The statistical delineation of the effect of the transgene and 
the time course of the neurodegenerative process on the expression 
pattern of Sirt1 and Sirt3 isoforms. In addition to the presented sta-
tistical differences, there were no significant interactions between the 
presence of the transgene and age. *p < 0.05, **p < 0.01, ***< 0.001; 
N.S. = not significant; tg = transgenic, wt = wild-type, w = weeks
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two isoforms. The expression level of cortical Sirt3-M2 in 
wt mice and striatal Sirt3-M3 in wt and tg mice decreased 
by 16 and 12 weeks of age, respectively.
The pattern of expression changes in the cerebellum 
regarding any of the assessed Sirt subtypes and isoforms 
strongly resembles to that of PGC-1α expression changes 
(either of its full length or N-terminal fragment) as we have 
shown in a previous study using the same animal model 
of HD [58]. The reason behind the same pattern may be 
that Sirtuins are upstream regulators of PGC-1α expression 
[8, 25]. Similar cerebellar predominant PGC-1α activation 
was induced by long-term physical exercise [47] and by 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treat-
ment in its acute phase [60], but not by cooling, by short-
term exercise [47], or by 3-nitropropionic acid (3-NP), the 
toxin used for modeling HD-associated striatal damage [58, 
65].
Although the cerebellum is known not to be the primar-
ily affected structure in HD, there is increasing evidence 
of its involvement in the pathomechanism of the disorder 
[48]. A considerable loss of Purkinje cells was demonstrated 
in some HD patients with predominant motor symptoms 
[51], the extent of which may become more pronounced 
in patients with higher CAG repeat number [19]. However, 
there is no clear relationship between the disease stage and 
the degree of Purkinje and granular cell loss, and the degree 
of cerebellar degeneration is quite variable [17, 23, 46]. The 
exact background of this variability, involving the sparing of 
alterations as well in some human cases, is not known and 
needs further elucidation. Nevertheless, some studies proved 
cerebellar hypermetabolism in HD [44] with a presumed 
compensatory role for dysfunction in the fronto-striato-
thalamic motor circuit [9, 53]. The significant elevations in 
cerebellar PGC-1α [58] and Sirt mRNA expressions in the 
N171-82Q HD model may be considered as an important 
part of this compensatory cerebellar hypermetabolism. Fur-
thermore, the increased Sirt3 mRNA expression indicates 
the involvement of mitochondrial activation as well. The 
beneficial role of the Sirt – PGC-1α axis in intact cerebellar 
functioning may be further supported by the finding that 
FL-PGC-1α knockout mice demonstrated reactive astroglio-
sis in cerebellar nuclei, whereas the striatum and cortex were 
almost totally spared [55]. Although data obtained from the 
above-mentioned toxin studies are somewhat controversial, 
this may be resolved by considering that in case of 3-NP 
the most vulnerable structures are the striatum and the hip-
pocampus, and not the cerebellum [34], whereas MPTP is 
capable of inducing cerebellar degeneration as well in addi-
tion to its well-known deleterious effects on the nigrostri-
atal system [57]. However, the mRNA expression changes 
in Sirt1 and Sirt3 levels following MPTP intoxication were 
not significant either in its acute or chronic phase (unpub-
lished data).
Regarding genotype-phenotype correlations, the first 
description of the applied N171-82Q transgenic mouse 
model of HD has already demonstrated that in addition to 
cortical, hippocampal, amygdalar and striatal involvement, 
an expressed deposition of intranuclear inclusions were 
present in cerebellar granule cells as well [49]. It was also 
verified by the authors, but no remarkable neuronal loss or 
reactive astrogliosis was found [40]. This may be explained 
by that the presence of abundant intranuclear inclusions 
does not compulsorily equals to severe neuronal damage, 
indeed, it was presumed to exert protective effects [3]. This 
may further support our hypothesis that coping mechanisms 
in the cerebellum, including inclusion body formation and 
enhanced expression pattern of the Sirt – PGC-1α axis, dem-
onstrated by the current and previous studies [59] of the 
authors, may be capable of exerting rather neuroprotective 
than damaging effects. Accordingly, the progression of the 
decrease of coordination, which was described as one of 
the key features of this model and probably attributed to 
cerebellar dysfunction, could be observed from 3 months of 
age on [20]. However, the hypokinetic feature of N171-82Q 
transgenic mice, rather explained by the dysfunction of the 
basal ganglia, involving the striatum, was still present at 8 
weeks of age [69]. The evidence from unbiased anatomi-
cal work-ups of the authors also favors the above-detailed 
hypothesis, i.e., more than 20% of striatal neurons contained 
intranuclear inclusions at 16 weeks of age, whereas no 
remarkable neuronal loss, but prominent neuronal atrophy 
could be detected at this age, responsible for the decrease of 
striatal volume and brain weight [69]. However, besides the 
well demonstrated atrophy of striatum, cortex, hippocampus, 
hypothalamus, thalamus and amygdala, the volume of the 
cerebellum was still preserved even at 18 weeks of age [6].
The characteristic pattern observed in preclinical findings 
could not be confirmed on human samples, where Sirt1, -2, 
and -3 mRNA levels were assessed, demonstrating elevated 
cortical and striatal Sirt1 and striatal Sirt2 expression in HD 
patients without any change regarding Sirt3 or the cerebel-
lum [4]. However, this gene expression study was carried out 
on post-mortem samples obtained from multiple centers, and 
the postmortem delay of sample handling and other char-
acteristics of the specimens were not given, so their effect 
on individual differences in mRNA decay cannot be ruled 
out introducing a bias into the results. Nevertheless, further 
human studies are needed to be able to better determine the 
human relevance of the current preclinical findings.
The major limitation of the current study is the lack of 
experiments on protein expression changes of the corre-
sponding Sirtuins. However, the widely applied antibody-
based methods in this topic (e.g. Western blotting) are semi-
quantitative at best, mostly lacking appropriate sensitivity 
and specificity [29]. Although the application of deep pro-
teomic analysis by mass spectrometry is appropriate, but 
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quite challenging [21], especially in case of brain samples 
with considerably high lipid content. Accordingly, this was 
out of the scope of the current study. Nevertheless, future 
experiments are needed to confirm the results of the present 
work at proteome level.
In conclusion, the current study demonstrates an unequiv-
ocal elevation of Sirt1 mRNA expression level in the cortical 
and cerebellar samples of HD transgenic animals compared 
to their age-matched wild-type littermates. An increase of 
these differences with aging could be observed only in the 
cerebellum of transgenic animals, presumably related to dis-
ease progression. Regarding the expression pattern of the 
mitochondrially acting Sirt3 isoforms (M1, M2, M3), which 
have not been assessed before in HD, a similar transgene-
specific increase of their cerebellar level was observed, and 
only the striatum showed a likewise elevation of exclusively 
the M3 isoform regarding the other 2 assessed brain regions. 
Accordingly, the observed pattern of changes with a pre-
sumed compensatory role may draw attention to that the 
involvement of cerebellum in HD may be more pronounced 
than previously thought, yielding a novel target for therapeu-
tic approaches aiming at symptom relief in that deleterious 
condition.
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